Nabriva: Plunges as COVID-19 curbs thwart approval of antibiotic

Nabriva Therapeutics

22/06/2020 11:51

** Shares of U.S. drug developer  NBRV.O  plunge 23.7% to 63
cents premarket as the FDA again declined to approve co's
antibiotic for complicated urinary tract infections
    ** NBRV worst performing stock across U.S. exchanges
premarket
    ** U.S. FDA cited manufacturing issues that could not be
resolved due to its inability to conduct onsite inspections
because of travel restrictions from the coronavirus outbreak
    ** FDA did not request any new clinical data or raise any
other concerns on efficacy or safety of the antibiotic, Contepo
 urn:newsml:reuters.com:*:nL4N2DX01Q
    ** Shares have fallen 37% YTD, as of Friday's close

 (Reporting by Saumya Sibi Joseph in Bengaluru)
 ((saumya.joseph@thomsonreuters.com))